{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:26:22Z","timestamp":1792805182918,"version":"4.5.0"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Carlos III Institute of Health, Ministry of Science and Innovation (Spain)","award":["RD21\/0016\/0019"],"award-info":[{"award-number":["RD21\/0016\/0019"]}]},{"name":"Carlos III Institute of Health, Ministry of Science and Innovation (Spain)","award":["RD24\/0005\/0013"],"award-info":[{"award-number":["RD24\/0005\/0013"]}]},{"name":"Carlos III Institute of Health, Ministry of Science and Innovation (Spain)","award":["B01_23R"],"award-info":[{"award-number":["B01_23R"]}]},{"name":"Carlos III Institute of Health, Ministry of Science and Innovation (Spain)","award":["B59_23D"],"award-info":[{"award-number":["B59_23D"]}]},{"name":"Gobierno de Aragon","award":["RD21\/0016\/0019"],"award-info":[{"award-number":["RD21\/0016\/0019"]}],"id":[{"id":"https:\/\/ror.org\/0425pg203","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Gobierno de Aragon","award":["RD24\/0005\/0013"],"award-info":[{"award-number":["RD24\/0005\/0013"]}],"id":[{"id":"https:\/\/ror.org\/0425pg203","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Gobierno de Aragon","award":["B01_23R"],"award-info":[{"award-number":["B01_23R"]}],"id":[{"id":"https:\/\/ror.org\/0425pg203","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Gobierno de Aragon","award":["B59_23D"],"award-info":[{"award-number":["B59_23D"]}],"id":[{"id":"https:\/\/ror.org\/0425pg203","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Union\u2019s Next Generation EU funds","award":["RD21\/0016\/0019"],"award-info":[{"award-number":["RD21\/0016\/0019"]}]},{"name":"European Union\u2019s Next Generation EU funds","award":["RD24\/0005\/0013"],"award-info":[{"award-number":["RD24\/0005\/0013"]}]},{"name":"European Union\u2019s Next Generation EU funds","award":["B01_23R"],"award-info":[{"award-number":["B01_23R"]}]},{"name":"European Union\u2019s Next Generation EU funds","award":["B59_23D"],"award-info":[{"award-number":["B59_23D"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Vitiligo is a pigmentation disorder that impacts approximately 0.5% to 2% of the global population. Growing interest surrounds the comorbidities associated with vitiligo. This study aimed to describe the socio-demographic characteristics of the patients with vitiligo in Arag\u00f3n (Spain) and to investigate their associated comorbidities. Methods: A retrospective observational study was conducted using clinical data from individuals in the EpiChron Cohort (reference population of 1.3 million) who were diagnosed with vitiligo between 1 January and 31 December 2019. The prevalence of chronic comorbidities was calculated using logistic regression models, obtaining the odds ratio (OR) of each comorbidity (dependent variable) according to the presence or absence of vitiligo (independent variable). We used a cut-off point for a statistical significance of p-value &lt; 0.05. Results: In total, 218 patients diagnosed with vitiligo were analyzed. The mean age was 44.0 years, and 56.42% were female. The largest proportion of patients (34.86%) were aged between 18 and 44 years. Among all vitiligo patients included, 71.5% presented multimorbidity, with an average of 3.21 diagnosed comorbidities. The conditions most frequently associated with vitiligo included thyroid disorders (OR: 3.01, p &lt; 0.001), ocular and hearing abnormalities (OR: 1.54, p &lt; 0.020), inflammatory skin disorders (OR: 2.21, p &lt; 0.001), connective tissue diseases (OR: 1.84, p &lt; 0.007), lower respiratory tract diseases (OR: 1.78, p &lt; 0.014), urinary tract infections (OR: 1.69, p &lt; 0.032), and cardiac arrhythmias (OR 1.84, p &lt; 0.034). Conclusions: This research highlights the importance of understanding the broader health implications of vitiligo and provides a foundation for further exploration into the complex interplay between this dermatologic condition and a diverse range of comorbidities.<\/jats:p>","DOI":"10.3390\/jcm14020432","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:42:15Z","timestamp":1736750535000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-3987","authenticated-orcid":false,"given":"Beatriz","family":"Clemente Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Dermatology, Miguel Servet University Hospital IIS Aragon, 50009 Zaragoza, Spain"},{"name":"Research Group of the Government of Aragon B59_23D Dermatology and Photobiology, Aragon Health, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Muelas Rives","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Miguel Servet University Hospital IIS Aragon, 50009 Zaragoza, Spain"},{"name":"Research Group of the Government of Aragon B59_23D Dermatology and Photobiology, Aragon Health, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-2076","authenticated-orcid":false,"given":"Tamara","family":"Gracia Caza\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Miguel Servet University Hospital IIS Aragon, 50009 Zaragoza, Spain"},{"name":"Research Group of the Government of Aragon B59_23D Dermatology and Photobiology, Aragon Health, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-3280","authenticated-orcid":false,"given":"Marcial","family":"\u00c1lvarez Salafranca","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Miguel Servet University Hospital IIS Aragon, 50009 Zaragoza, Spain"},{"name":"Research Group of the Government of Aragon B59_23D Dermatology and Photobiology, Aragon Health, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-5093","authenticated-orcid":false,"given":"Beatriz","family":"Poblador-Plou","sequence":"additional","affiliation":[{"name":"EpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Arag\u00f3n), Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2903-8159","authenticated-orcid":false,"given":"Clara","family":"Laguna-Berna","sequence":"additional","affiliation":[{"name":"EpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Arag\u00f3n), Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-3278","authenticated-orcid":false,"given":"Aida","family":"Moreno Juste","sequence":"additional","affiliation":[{"name":"EpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Arag\u00f3n), Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain"},{"name":"Aragon Health Service (SALUD), 50003 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-1710","authenticated-orcid":false,"given":"Antonio","family":"Gimeno-Miguel","sequence":"additional","affiliation":[{"name":"EpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Arag\u00f3n), Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-3617","authenticated-orcid":false,"given":"Yolanda","family":"Gilaberte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Miguel Servet University Hospital IIS Aragon, 50009 Zaragoza, Spain"},{"name":"Research Group of the Government of Aragon B59_23D Dermatology and Photobiology, Aragon Health, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Schallreuter","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/ijd.14055","article-title":"Comorbidities in vitiligo: Comprehensive review","volume":"57","author":"Dahir","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamadermatol.2023.2162","article-title":"Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US","volume":"159","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: Towards a new management algorithm","volume":"37","author":"Speeckaert","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on Vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.abd.2021.09.008","article-title":"Update on the pathogenesis of vitiligo","volume":"97","author":"Marchioro","year":"2022","journal-title":"An. Bras. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: Mechanisms of Pathogenesis and Treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: The European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jdv.14792","article-title":"Critical appraisal of the oxidative stress pathway in vitiligo: A systematic review and meta-analysis","volume":"32","author":"Speeckaert","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: An Update on Pathophysiology and Treatment Options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: Systematic review and Meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_14","first-page":"1309","article-title":"Therapeutic management of vitiligo","volume":"16","author":"Bleuel","year":"2018","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, From Physiopathology to Emerging Treatments: A Review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/pcmr.12878","article-title":"The enigma and challenges of vitiligo pathophysiology and treatment","volume":"33","author":"Jordan","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","article-title":"Comorbidities in Patients with Vitiligo: A Systematic Review and Meta-Analysis","volume":"143","author":"Lee","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmed.2023.1072837","article-title":"Beyond skin white spots: Vitiligo and associated comorbidities","volume":"10","author":"Hu","year":"2023","journal-title":"Front. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1684\/ejd.2018.3449","article-title":"Vitiligo and thyroid disease: A systematic review and meta-analysis","volume":"28","author":"Fan","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"382e","DOI":"10.1093\/ije\/dyx259","article-title":"Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study","volume":"47","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"ref_21","unstructured":"Dea, M.L.C., Bellid, E.O., Solana, C.F., Palacio, I.A., Del Hombrebueno, G.G.-C.R., and Sancho, B.A. (2018). [Construction of a Deprivation Index by Basic Healthcare Area in Aragon Using Population and Housing Census 2011]. Rev. Esp. Salud. Publica, 92, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/30531710\/."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Moreno-Juste, A., Gimeno-Miguel, A., Poblador-Plou, B., Calder\u00f3n-Larra\u00f1aga, A., del Pozo, M.C., Forjaz, M.J., Prados-Torres, A., and A Gimeno-Feli\u00fa, L. (2023). Multimorbidity, social determinants and intersectionality in chronic patients. Results from the EpiChron Cohort. J. Glob. Health, 13.","DOI":"10.7189\/13.04014"},{"key":"ref_23","unstructured":"(2024, December 24). Clinical Classifications Software (CCS) for, I.C.D.-9.-C.M, Available online: https:\/\/hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp."},{"key":"ref_24","unstructured":"(2024, December 24). Indicador de Condici\u00f3n Cr\u00f3nica (ICC) para, C.I.E.-9.-C.M, Available online: https:\/\/hcup-us.ahrq.gov\/toolssoftware\/chronic\/chronic.jsp."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Almenara-Blasco, M., Carmona-P\u00edrez, J., Gracia-Caza\u00f1a, T., Poblador-Plou, B., P\u00e9rez-Gilaberte, J.B., Navarro-Bielsa, A., Gimeno-Miguel, A., Prados-Torres, A., and Gilaberte, Y. (2022). Comorbidity Patterns in Patients with Atopic Dermatitis Using Network Analysis in the EpiChron Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216413"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1590\/S0365-05962011000200006","article-title":"Vitiligo epidemiological profile and the association with thyroid disease","volume":"86","author":"Nunes","year":"2011","journal-title":"An. Bras. Dermatol."},{"key":"ref_27","first-page":"845","article-title":"Vitiligo and autoantibodies: A systematic review and meta-analysis","volume":"16","author":"Liu","year":"2018","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00403-023-02661-y","article-title":"Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: A nationwide cross-sectional study","volume":"315","author":"Silverberg","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/ced.14649","article-title":"Ocular and auditory abnormalities in patients with vitiligo: A case\u2013control study","volume":"46","author":"Genedy","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/0378-6323.32710","article-title":"Vitiligo: A part of a systemic autoimmune process","volume":"73","author":"Gopal","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Rashighi, M., and Harris, J.E. (2017). Vitiligo pathogenesis and emerging treatments. Dermatol. Clin., 35.","DOI":"10.1016\/j.det.2016.11.014"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy","volume":"54","author":"Boniface","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Richmond, J.M., and Harris, J.E. (2014). Immunology and skin in health and disease. Cold Spring Harb. Perspect. Med., 4.","DOI":"10.1101\/cshperspect.a015339"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.15550","article-title":"Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: Relevance for cutaneous lupus and vitiligo pathogenesis","volume":"177","author":"Jacquemin","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s13555-023-01001-2","article-title":"Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis","volume":"13","author":"Ezzedine","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1203475415615326","article-title":"A Case of Colocalized Vitiligo and Psoriasis","volume":"20","author":"Langley","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Srivastava, P., Talwar, M., Yadav, A., Choudhary, A., Mohanty, S., Bharti, S., Narad, P., and Sengupta, A. (2021). VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using coexpression network-based approach. F1000Res., 9.","DOI":"10.12688\/f1000research.25713.2"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chung, S.A., and Criswell, L.A. (2007). PTPN22: Its role in SLE and autoimmunity. Autoimmunity, 40.","DOI":"10.1080\/08916930701510848"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1073\/pnas.1525001113","article-title":"Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo","volume":"113","author":"Hayashi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1126\/science.1176077","article-title":"Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells","volume":"325","author":"Pan","year":"2009","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2016.09.021","article-title":"Multiple Functional Variants of IFIH1, a Gene Involved in Triggering Innate Immune Responses, Protect against Vitiligo","volume":"137","author":"Jin","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1222808110","article-title":"NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1\u03b2 processing via the NLRP1 inflammasome","volume":"110","author":"Levandowski","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jid.2010.337","article-title":"Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP","volume":"131","author":"Birlea","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression","volume":"137","author":"Rezk","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0190-9622(96)90656-8","article-title":"Orbital myositis, vitiligo, and giant cell myocarditis","volume":"35","author":"Stevens","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.reuma.2020.06.009","article-title":"Infecciones en enfermedades autoinmunes sist\u00e9micas","volume":"17","year":"2021","journal-title":"Reumatol. Clin."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1346-8138.15290","article-title":"Increased risk of psychiatric disorders in adult patients with vitiligo: A nationwide, population-based cohort study in Taiwan","volume":"47","author":"Chen","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kussainova, A., Kassym, L., Akhmetova, A., Glushkova, N., Sabirov, U., Adilgozhina, S., Tuleutayeva, R., and Semenova, Y. (2020). Vitiligo and anxiety: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241445"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Padmakar, S., Murti, K., Pandey, K., Kumari, S., Kumar, R., Siddiqui, N.A., and Pal, B. (2022). Suicidal ideation associated with vitiligo\u2014A systematic review of prevalence and assessment. Clin. Epidemiol. Glob. Health, 17.","DOI":"10.1016\/j.cegh.2022.101140"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:26:56Z","timestamp":1759919216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/2\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14020432"],"URL":"https:\/\/doi.org\/10.3390\/jcm14020432","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]}}}